Skip to main content
. 2022 Jan 3;22:31. doi: 10.1186/s12885-021-09137-0

Fig. 1.

Fig. 1

The overall survival in the eribulin and non-eribulin groups (A), eribulin group of patients who received eribulin at an early line (first or second) and non-eribulin group (B) and eribulin group of patients who received eribulin at a late line (third or later) and non-eribulin group (C). CI: confidence interval, OS: Overall survival